Q1 FY27 Earnings Call Transcript: EU-GMP Final Report Expected in 2 Weeks
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zim Laboratories Q1 FY27 revenue grew 31.2% YoY to INR 942 million, but EBITDA margin was just 3.7% (INR 34 million) and PAT was negative INR 40 million due to higher employee and EU-GMP related costs. Exports were 84% of income, NIP and OTF portfolio 18%. Management said EU-GMP final report expected within 2 weeks with no critical observations. They guided 10-15% growth in FY27 without EU and 30-35% growth in FY28 with EU approval and mid-teens EBITDA margins. About 8-10 market approvals are ready once EU clearance comes.
Key catalyst is EU-GMP approval expected within 2 weeks; current margins weak but FY28 growth and margin outlook positive subject to clearance.